Al-Herz Waleed, Husain Entesar H, Adeli Mehdi, Al Farsi Tariq, Al-Hammadi Suleiman, Al Kuwaiti Amna Ali, Al-Nesf Maryam, Al Sukaiti Nashat, Al-Tamemi Salem, Shendi Hiba
From the Department of Pediatrics, Faculty of Medicine, Kuwait University, Kuwait City, Kuwait.
Allergy and Clinical Immunology Unit, Pediatric Department, Al-Sabah Hospital, Kuwait City, Kuwait.
Pediatr Infect Dis J. 2022 Nov 1;41(11):933-937. doi: 10.1097/INF.0000000000003678. Epub 2022 Sep 7.
To present the details of Bacillus Calmette-Guérin (BCG)-vaccine associated complications (VACs) in combined immunodeficiencies (CID) patients.
Five centers participated in this retrospective study and completed a data form, which included general patients' information, clinical and laboratory data.
Among 236 CID patients, 127 were BCG vaccinated. 41.9% of patients with family history of CID and 17.1% who were diagnosed by screening were BCG vaccinated. Twenty-three patients (18.1%) developed BCG-VACs. The median age of VACs was 6 months and the median time from vaccination to complications was 6 months. The highest rate of BCG-VACs was recorded in patients receiving the Russian BCG strain compared to the Tokyo and Danish strains. Univariate analysis of T-lymphocyte subsets showed increased odds of BCG complications in patients with CD3+, CD4+, and CD8+ counts of ≤250 cells/µL. Only CD8 + count ≤250 cells/µL had increased such odds on multivariate analysis. VACs were disseminated in 13 and localized in 10 patients. Localized complication occurred earlier after vaccination (median: 4 months) compared with disseminated ones (median: 7 months). There were no significant associations between sex, administered vaccine strain, serum immunoglobulins levels, lymphocyte subsets counts, and the chance of having either localized or disseminated BCG-related complications.
Although contraindicated, many patients with CID continue to be vaccinated with BCG. Low CD8 + count is a risk factor for BCG-related complications and localized complications occurred earlier than disseminated ones. Considerations should be undertaken by health care authorities especially in countries with high incidence of CID to implement newborn screening, delay the time of BCG vaccine administration beyond 6 months of age and to use the relatively safer strains like the Danish and Tokyo ones.
阐述卡介苗(BCG)疫苗相关并发症(VACs)在联合免疫缺陷(CID)患者中的详细情况。
五个中心参与了这项回顾性研究,并填写了一份数据表格,其中包括患者的一般信息、临床和实验室数据。
在236例CID患者中,127例接种了BCG疫苗。有CID家族史的患者中41.9%接种了BCG疫苗,通过筛查确诊的患者中17.1%接种了BCG疫苗。23例患者(18.1%)发生了BCG-VACs。VACs的中位年龄为6个月,从接种疫苗到出现并发症的中位时间为6个月。与东京株和丹麦株相比,接受俄罗斯BCG株的患者中BCG-VACs发生率最高。对T淋巴细胞亚群的单因素分析显示,CD3+、CD4+和CD8+计数≤250个细胞/微升的患者发生BCG并发症的几率增加。多因素分析显示,只有CD8+计数≤250个细胞/微升时,这种几率才会增加。13例患者发生了播散性VACs,10例患者发生了局限性VACs。局限性并发症在接种疫苗后出现得更早(中位时间:4个月),而播散性并发症出现得较晚(中位时间:7个月)。性别、接种的疫苗株、血清免疫球蛋白水平、淋巴细胞亚群计数与发生局限性或播散性BCG相关并发症的几率之间无显著关联。
尽管有禁忌,但许多CID患者仍继续接种BCG疫苗。低CD8+计数是BCG相关并发症的危险因素,局限性并发症比播散性并发症出现得更早。卫生保健当局应予以考虑,特别是在CID发病率高的国家,实施新生儿筛查,将BCG疫苗接种时间推迟到6月龄以后,并使用丹麦株和东京株等相对更安全的菌株。